Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference

Arno Therapeutics, Inc. ARNI, a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that a late-breaking abstract on AR-12 has been accepted for poster presentation at the upcoming 15th European AIDS Conference, hosted by the European AIDS Clinical Society (EACS) and being held October 21-24 in Barcelona, Spain. Logistical details for the poster presentation include: Poster PE6/4: AR-12, a Novel First in Class Host Cell Targeting Therapeutic Candidate with Potent Activity Against HIV Multidrug Resistant Strains in vitro First Author: Stefan Proniuk, PhD Date, Time: Wednesday, October 21 at 3:00 p.m. CEST through Saturday, October 24 at 12:00 p.m. CEST Location: Exhibition Area, Level 0
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!